Companies / Singapore
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Second Phase Of Biomedical Initiative Under Way
November 2006 | Company Finance AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Singapore has completed the first phase of its Biomedical Science (BMS) initiative, and is keen to push on to phase II, which will have government investment of US$1.4bn. Under the initial plans, which ran from 2000-2005, Singapore grew its drug manufacturing output to SGD18bn (US$11.61bn), 50% higher than its target of SGD12bn (US$7.74bn). Meanwhile, eight out of the top 20 drugmakers have facilities in the country, although mainly to produce active pharmaceutical ingredients (APIs).